Daniel Kavanagh, PhD, RAC
Senior Scientific Advisory, Gene Therapy, Vaccines and Biologics, WCG
Biography
Daniel Kavanagh, PhD, RAC, is the senior scientific advisor of gene therapy, vaccines, and biologics at WCG. Prior to joining WCG, he was assistant professor of medicine and Institutional Biosafety Committee vice chair at Harvard Medical School, and assistant immunologist at the Massachusetts General Hospital. He was also co-chair of a Phase 1 clinical trial of a therapeutic mRNA vaccine. He is certified in US Regulatory Affairs (RAC) by the Regulatory Affairs Professional Society.
Latest insights by Daniel
Precision Oncology & Biomarker Driven Clinical Trials
Advancing Precision Medicine: Harnessing Molecular Biomarkers for Oncology Clinical Trials
Blog Posts
Clinical Trial Safety
Spotlighting Lupus Awareness Month: CAR-T Technology Creates New Avenues for Treatment of a Devastating Disease
Blog Posts
Biosafety
Ask the Experts: Submitting Separate Information Between Studies and Sites
Blog Posts
Series: WCG Talks Trials
The Ethical and Safety Considerations of Accelerating Oncology Trials
Podcasts
Series: WCG Trends & Insights for 2024
The Decentralization of Vaccines in 2024 and Beyond
Blog Posts
Cell & Gene Therapy
Key Takeaways From FDA’s New Draft Guidance, “Studying Multiple Versions of a Cellular or Gene Therapy Product in an Early-Phase Clinical Trial”
Blog Posts
Cell & Gene Therapy
Four Key Elements You Need to Know About the Role of IBCs in Gene Therapy Trials
Blog Posts
Cell & Gene Therapy
As a sponsor, does my HGT clinical trial require IBC approval at all sites?
Blog Posts
Cell & Gene Therapy
Does Human Gene Transfer research at my site require IBC approval?
Blog Posts